MétaCan
Menu
← Back to cohort
Record W4405038608 · doi:10.1182/blood-2024-204052

Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis

2024· article· en· W4405038608 on OpenAlexaff
Nihar Desai, Tommy Alfaro Moya, Igor Novitzky‐Basso, Ivan Pašić, Wilson Lam, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Dennis Dong Hwan Kim, Rajat Kumar, Jonas Mattsson, Arjun Law

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldMedicine
TopicRenal Transplantation Outcomes and Treatments
Canadian institutionsUniversity of TorontoUniversity Health NetworkPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineSiblingTolerabilityTransplantationCyclophosphamideRetrospective cohort studyInternal medicineSurgeryPediatricsAdverse effectChemotherapyPsychology

Abstract

fetched live from OpenAlex

Introduction: Post-transplant cyclophosphamide (PTCy) is a safe and effective graft versus host disease (GVHD) prophylaxis strategy. While initially established as the standard of care for haploidentical allogeneic hematopoietic cell transplantation (alloHCT), its use is now expanding to HLA-matched unrelated donors (MUD), and HLA-matched sibling donors (MSD) alloHCT. However, there is limited evidence of its safety in older adults (>60 years). We evaluated the tolerability of PTCy in older adults undergoing alloHCT from a MSD and compared the outcomes with an older cohort using a conventional regimen of calcineurin inhibitor (CnI) and methotrexate (MTX). Methods: We retrospectively analyzed patients receiving MSD alloHCT between August 2010 and March 2023. Overall survival (OS) and GVHD-free/relapse-free survival (GRFS) were estimated using the Kaplan-Meier method and the difference between groups was assessed using the log-rank test. Cumulative incidences (CI) of relapse (CIR), Non-relapse Mortality (NRM), acute and chronic GVHD, and bloodstream infections (BSI) were analyzed using competing risk models. A p-value of <0.05 was considered statistically significant and analyses were performed using EZR (version 1.62). Results: One-hundred and two patients underwent MSD alloHCT. The standard GVHD prophylaxis regimen for MSD alloHCT was a combination of CnI and MTX (n=69) between August 2010 and June 2019. Starting in June 2019, the GVHD prophylaxis protocol was revised to PTCy, CnI, and mycophenolate mofetil (MMF) (n=33). The baseline characteristics were similar between the groups except for a higher use of cryopreserved grafts in the CnI+MTX group (65.2 % vs 3%; p<0.001). The median follow-up after alloHCT was 16.4 months (11 - 22) for the PTCy group and 41 months (34 - 48) for the Cni-MTX group (p=0.001) The median age of the cohort was 65 years (62 - 68), and 58 (56.8%) were male. Acute myeloid leukemia was the most common indication for alloHCT (n=57, 55.9%). The majority (n=99, 97%) received reduced-intensity conditioning. Peripheral blood was the graft source for all patients, with a median CD34+ cell dose of 6.5 x 106/kg (5.6 - 7.9). The median time to neutrophil engraftment was 19 days (17-21) in the PTCy group versus 17 days (16-19) in the Cni+MTX group (p=0.22). The median time to platelet engraftment was 20 days (18-27) for PTCy and 16 days (14-18) for the Cni+MTX group (p=0.09). Graft failure occurred in 2 patients (1.9%), both in the CNI+MTX group. The median time to discontinuation of immunosuppression was 82 days (69-107) in the PTCy group and 139 days (100-282) in the CnI+MTX group (p=0.008). At D+100, the CI of aGVHD grade II-IV was significantly lower in the PTCy group [25.3% (11.7 - 41.5) vs 29.3% (19 - 40); p=0.04]. There was no significant difference in grade III-IV acute GVHD between the groups [8% (range: 1.3-23) vs. 8.3% (range: 3-17); p=0.15]. Moderate to severe cGVHD occurred in 35.8% (12.5-60.3) of the PTCy group versus 51.5% (38.6-62.9) in the CnI-MTX group (p=0.14). The CI of clinically significant CMV viremia (>500 IU/mL) at D+100 was 36.4% (20 -52) in the PTCy group and 36.2% (25 - 47) in the CnI+MTX group; p=0.67. No patient developed CMV end organ damage. There were 2 episodes of EBV reactivation, both in the PTCy group. The D+100 incidence of BSI was 60.6 % (42 - 75) and 17.4% (10 -27) in the PTCy and CnI+MTX groups, respectively (p<0.001). The NRM at 1 year was 9.7% (2 - 23) and 31.9% (21 - 43) in the PTCy and CnI+MTX groups, respectively (p=0.04). The CI of relapse at 2 years was 28.2% (12-47) for the PTCy group and 17.4% (9 -27) in the CnI+MTX group (p=0.4). The GRFS at 1 year was 40% (22 - 57) in the PTCy group versus 5.4% (2 - 13) in the Cni+MTX group (p=0.003). The OS at 2 years was 54.8% (31-73) in the PTCy group and 46.4% (34-58) in the CnI+MTX group (p=0.28). Conclusion: PTCy significantly reduces the incidence of acute GVHD and NRM, while improving GRFS in older adults undergoing MSD alloHCT. However, patients receiving PTCy have higher rates of bloodstream infections. PTCy shows comparable rates of viral reactivation, relapse, and OS to conventional regimens. The delayed engraftment for platelets and neutrophils does not correlate with a higher incidence of graft failure. Further studies are warranted to validate these findings.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.264
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicRenal Transplantation Outcomes and Treatments→French-language works237,207→